Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation

Steven Andrew Baker*, Shirley Kwok, Gerald J. Berry, Thomas J. Montine

Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of America

* sab73@stanford.edu

Abstract

Mortality due to Covid-19 is highly associated with advanced age, owing in large part to severe lower respiratory tract infection. SARS-CoV-2 utilizes the host ACE2 receptor for infection. Whether ACE2 abundance in the lung contributes to age-associated vulnerability is currently unknown. We set out to characterize the RNA and protein expression profiles of ACE2 in aging human lung in the context of phenotypic parameters likely to affect lung physiology. Examining publicly available RNA sequencing data, we discovered that mechanical ventilation is a critical variable affecting lung ACE2 levels. Therefore, we investigated ACE2 protein abundance in patients either requiring mechanical ventilation or spontaneously breathing. ACE2 distribution and expression were determined in archival lung samples by immunohistochemistry (IHC). Tissues were selected from the specimen inventory at a large teaching hospital collected between 2010–2020. Twelve samples were chosen from patients receiving mechanical ventilation for acute hypoxic respiratory failure (AHRF). Twenty samples were selected from patients not requiring ventilation. We compared samples across age, ranging from 40–83 years old in the ventilated cohort and 14–80 years old in the non-ventilated cohort. Within the alveolated parenchyma, ACE2 expression is predominantly observed in type II pneumocytes (or alveolar type II / AT2 cells) and alveolar macrophages. All 12 samples from our ventilated cohort showed histologic features of diffuse alveolar damage including reactive, proliferating AT2 cells. In these cases, ACE2 was strongly upregulated with age when normalized to lung area (p = 0.004) or cellularity (p = 0.003), associated with prominent expression in AT2 cells. In non-ventilated individuals, AT2 cell reactive changes were not observed and ACE2 expression did not change with age when normalized to lung area (p = 0.231) or cellularity (p = 0.349). In summary, ACE2 expression increases with age in the setting of alveolar damage observed in patients on mechanical ventilation, providing a potential mechanism for higher Covid-19 mortality in the elderly.
Introduction

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic of related illness grouped under the term coronavirus disease 2019 (Covid-19) [1]. Manifestations include both upper and lower respiratory infection as well as various non-respiratory organ system disturbances [2–6], including renal [7], gastrointestinal [8] and vascular abnormalities [9]. The vast majority of deaths result from lower respiratory tract infection leading to acute respiratory distress syndrome (ARDS) with the pathological findings of diffuse alveolar damage (DAD) [10, 11].

Risk factors for severe respiratory illness include hypertension [12], diabetes [12], obesity [13], cancer [14], chronic respiratory illness [15], male sex [13], and particularly advanced age [16–18]. For each year of age, the odds ratio of death has been estimated to increase by 1.1 in multivariable analysis [16]. Among individuals admitted to the ICU for Covid-19, risk of death for those ≥ 64 years old is 2.4-fold greater than those younger [19]. In contrast, mortality among children infected with SARS-CoV-2 is exceedingly rare compared to middle-aged individuals [20], a feature which is atypical for respiratory viruses [21]. The underlying reasons for this dramatic skew are currently unknown [22].

SARS-CoV-2 depends on the angiotensin-converting enzyme 2 (ACE2) protein for attachment to and infection of host cells [23]. ACE2 is a transmembrane metalloprotease belonging to the Renin–Angiotensin–Aldosterone System (RAAS) which processes angiotensin II into angiotensin 1–7 leading to vasodilation [24]. The gene encoding ACE2 (Angiotensin I converting enzyme 2, Ace2) exhibits strong RNA expression in the kidney, lung, bladder, stomach, small intestine, large intestine, and adipose tissue of rodents [25]. In rats, lung ACE2 protein expression has been shown to drastically decrease with age [26], raising the question of why older individuals are more susceptible to severe lower respiratory infection than the young [27]. Previous studies of ACE2 levels in the human lung have revealed no significant change with respect to age in bulk RNA sequencing (RNAseq) analysis [28, 29]. Similar findings have been observed in single cell RNA (scRNA) expression data for Ace2 in rodents [29]. In order to investigate this apparent paradox, we reexamined publicly available ACE2 RNAseq data from human lungs [30], adjusting for various donor phenotypes. Our analyses reveal a significant increase in detected ACE2 RNA levels associated with mechanical ventilation. After including the effect of mechanical ventilation, we find that ACE2 expression increases with age in human lung samples from deceased donors. Although RNA levels often correlate with protein expression, exceptions are common [31, 32]. We sought to validate our findings at the RNA level by investigating ACE2 protein expression in archival human lung tissue from patients receiving supportive mechanical ventilation. Consistently, ACE2 protein expression strongly increased with age in patients requiring mechanical ventilation. These findings, at both the RNA and protein level, provide a potential explanation for the preponderance of severe Covid-19 cases among the elderly.

Materials and methods

RNAseq analysis

Normalized gene expression data and subject phenotypes from the NIH Genotype-Tissue Expression (GTEx) project version 8 (dbGaP accession phs000424.v8.p2, released 8/26/2019) were acquired from the GTEx Portal [33]. These data include 17,382 samples from 948 deceased human donors. Expression scores in Transcripts Per Kilobase Million (TPM) were extracted for ACE2 from each sample and analyzed using R version 3.5.0. The expression for lung was plotted using ggplot2 stratified by donor age, sex, and/or the Hardy scale score (see S
Methods in S1 File), which are provided through the portal [33]. A linear model was fit using the \textit{lm} function in base R to predict ACE2 expression with age, sex, and Hardy score as covariates. Primary analyses were carried out on linear TPM data to facilitate interpretation. The significance and direction of the effects were confirmed after Box-Cox transformation of lung ACE2 expression using $\lambda_{\text{MLE}}$ computed by the MASS package in R. Mouse scRNAseq data [34] for Ace2 expression were obtained from the Tabula Muris portal [35] and droplet sequencing results for lung were plotted using ggplot2 in R.

Immunohistochemistry (IHC)

All aspects of this study were approved by the Stanford Institutional Review Board under protocol #33727. Formalin-fixed paraffin-embedded (FFPE) human lung excisions/biopsies received through Stanford Surgical Pathology during 2010–2020. To allow for blinding, cases were chosen by 1 investigator who did not participate in specimen preparation or data acquisition and analyses until all data had been collected. We identified a set of 20 patients who were not on mechanical ventilation (other than for procedural anesthesia) and a set of 11 patients who required supportive ventilation for acute hypoxic respiratory failure (AHRF); either idiopathic or in the setting of advanced fibrotic interstitial lung disease. Patients in our non-ventilated cohort ranged from 14 to 80 years of age (mean 41.6 +/- 23.1 years). Patients in our ventilated cohort ranged from 40 to 83 years old (mean 56.8 +/- 12.3 years). Sections were stained using standard procedures (see S Methods in S1 File) with a commercial antibody raised against human ACE2 (Abcam, ab15348). Subsequent control sections were stained with Hematoxylin and Eosin (H&E) using standard procedures (S1A–S1D Fig in S1 File). All comparisons were made using sections that were stained in a single batch and imaged and processed using identical conditions (S2 Fig in S1 File).

Image collection and quantification

Sections were imaged on a Nikon Eclipse E1000 using a Spot Insight 12 MP CMOS camera with the manufacturer’s provided software. A single inflated field within each slide was selected using a 1x objective from which to start image collection by switching to the 20x objective. Using the 20x objective, 5 adjacent/sequential fields were collected. Images used for quantification were obtained by an investigator without knowledge of the patients’ ages. ACE2 and cellular quantification were carried out using ImageJ (see S Methods in S1 File). The relationship of age to these measures was analyzed by simple linear regression using the \textit{lm} function in R.

Clinical feature comparison

Chart review was performed for each specimen from the ventilated cohort to determine the contribution of various features to ACE2 staining intensity. These parameters included: the date the sample was collected and preserved for archiving, the ventilation parameters used to support the patient closest in time to specimen collection (i.e., the fraction of inspired oxygen or FiO$_2$ and positive end-expiratory pressure or PEEP), the severity of DAD in the collected specimen graded by a board certified pathologist using the DAD Score [36] with minor modifications (see S Methods in S1 File), a clinical diagnosis of interstitial lung disease (ILD), a documented history of tobacco smoking, and patient sex. These features were compared to lung ACE2 staining using linear regression for continuous variables or the Wilcoxon rank-sum test for categorical variables.
Additional statistical analyses
Data were analyzed using R version 3.5.0 unless otherwise stated, the technical details are outlined above and as described in S Methods in S1 File. For multiple regression, no interaction terms were included. Outliers were not removed from any analysis. No power analysis was performed to determine the cohort sizes, sample size for the ventilated patient cohort was determined by tissue availability and feasibility of access. Pairwise comparisons were made using the Wilcoxon rank-sum test. A threshold of \( p < 0.05 \) was set for statistical significance, no correction for multiple testing was applied due to the limited number of statistical tests employed. All tests were two-tailed, between group comparisons.

Results
To understand the age-related pattern of \( \text{ACE2} \) abundance in the human lung we utilized the large, harmonized RNAseq dataset available from the GTEx consortium [30]. GTEx version 8 contains data from 578 unique deceased donor lungs, binned by decade of age at death [33]. In unadjusted analysis, \( \text{ACE2} \) expression was not significantly associated with age \( (\beta = 0.082 \text{ TPM/decade}, p = 0.227, \text{linear regression}) \) or sex \( (p = 0.303, \text{Wilcoxon rank-sum test}) \) (Fig 1A and 1B). The dataset also describes the mode of death, summarized by the Hardy scale [37], which categorizes clinical circumstances proximate to the end of life. The strongest category associated with \( \text{ACE2} \) expression was ventilation at the time of death showing a 103\% increase in median \( \text{ACE2} \) levels \( (0.715 \text{ TPM without vs. } 1.452 \text{ TPM with ventilation, } p < 1 \times 10^{-15}, \text{Wilcoxon rank-sum test}) \). Lung \( \text{ACE2} \) expression, when stratified by Hardy score, revealed a significant relationship with age; expression of \( \text{ACE2} \) increased by 0.208 TPM for every decade of life \( (p = 0.003, \text{multivariable regression}), \) or a 14\% increase each decade when compared to individuals in their 20’s (Fig 1C). Transcript abundance from deceased donors can be affected by the tissue ischemic time that transpires prior to sample stabilization [38]. In order to assess whether this variable contributes to \( \text{ACE2} \) abundance from deceased donor lungs, we

![Fig 1. ACE2 RNA expression increases with age and mechanical ventilation in the lung. A) Human lung ACE2 expression is colored by decade of life when the individual died. In unadjusted linear regression, there was no significant effect of age on ACE2 expression (p = 0.227, n = 578 individuals). B) ACE2 expression in lung stratified by sex. Analysis adjusted for age and sex, revealed no significant effect for either variable (p = 0.228 for age, p = 0.920 for sex, multivariate regression, n = 395 males, n = 183 females). There was also no significant difference when compared by sex alone (p = 0.303, Wilcoxon rank-sum test). C) ACE2 expression in lung stratified by the Hardy scale. This scale indicates the length of time spent in the terminal phase before death, which is depicted above each grouping of data points. Within each Hardy scale group, the data are sub-stratified by age. (n = 26 for a score of 1 representing a violent and fast death lasting < 10 minutes, n = 136 for a score of 2 representing a fast death by natural causes lasting 10 minutes–1 hour, n = 31 for a score of 3 representing an intermediate rate of death lasting 1 hour–24 hours, n = 64 for a score of 4 representing a slow death with a terminal phase lasting > 24 hours, n = 299 for a score of 0 representing donors supported by a ventilator preceding death, n = 2 with an unknown score). For all panels, each point represents a sample from a unique individual. Box plots indicate quartiles. A linear model fit to the data is inset, indicating the estimated coefficient for age (\( \beta_i \)) and its significance.](https://doi.org/10.1371/journal.pone.0247060.g001)
incorporated this feature as a covariate in our model (S3 Fig in S1 File). The contribution of tissue ischemic time to ACE2 expression was not significant (β = -0.0003 TPM/minute, p = 0.248) and did not change the effect of age on ACE2 expression or its significance (β = 0.212 TPM/decade, p = 0.002). We also compared ACE2 expression across the human body. Interestingly, when controlling for the manner of death, the lung exhibited the most significant increase in ACE2 expression with age over all tissues (S1 Table in S1 File).

In order to characterize ACE2 protein abundance in the lung, we validated a commercial antibody directed against this key viral receptor (S4A and S4B Fig in S1 File). Prior analysis of ACE2 localization by IHC revealed strong enrichment within the luminal surface of cortical tubule cells of the kidney and enterocytes of the small intestine [39]. Our ACE2 IHC staining on healthy control tissue revealed a strikingly similar pattern, which highlighted the kidney cortex and specifically the apical membrane of brush border cells (S4A Fig in S1 File). We also detected strong ACE2 expression along villi and the apical membranes of small intestine enterocytes (S4B Fig in S1 File). Within the lung, ACE2 has been shown to localize to epithelial cells of the alveolus [39]. Data from murine scRNAseq reveal detectable expression of Ace2 within type II pneumocytes (or alveolar type II / AT2 cells), ciliated columnar cells, alveolar macrophages, and to a lesser extent, stromal cells (S5 Fig in S1 File). Consistent with these data, our IHC revealed strong ACE2 staining within AT2 cells in normal alveoli, concentrated within the membrane, as well as alveolar macrophages (Fig 2). Taken together, these data indicate that our staining protocol accurately identifies ACE2 expressing cells within human tissue, including the lung. Therefore, we investigated whether the distribution of ACE2 in the lung is associated with ventilation and age.

We identified 12 lung samples from 11 patients requiring mechanical ventilation for AHRF available from our institution’s archive. All 11 patients had DAD (S2 Table in S1 File), a pathological finding consistently observed in patients with severe Covid-19 lower respiratory disease [10, 11]. All tissue was collected prior to 2019 (range 2010–2018), excluding the possibility of SARS-CoV-2 involvement. H&E control sections revealed the expected histologic findings, depending on the phase of DAD, with reactive AT2 hyperplasia, hyaline membrane formation, interstitial thickening and/or fibrosis, and exudative edema (S1B Fig in S1 File). When stained by IHC, prominent ACE2 expression within the alveolar parenchyma was observed in reactive AT2 cells with increasing ACE2 staining intensity detected with advanced age (Fig 3A and 3B). ACE2 expression was quantified either by normalizing to tissue area (Fig 3C) or...
Fig 3. ACE2 protein expression increases with age in ventilated patients. A) Representative images of lung stained for ACE2 from a 40-year-old man with acute lung injury are shown using a 1x objective (left, scale bar 3mm) with the region outlined by the red dashed box magnified at low power (middle, scale bar 200μm) and a second field at high power (right, scale bar 50μm). Clusters of reactive AT2 cells (red arrowheads) are present along the alveolar septum which exhibit low level ACE2 expression.

B) Representative images of lung stained for ACE2 from a 67-year-old man with acute lung injury superimposed on fibrosing interstitial lung disease are shown using a 1x objective (left, scale bar 3mm) with the region outlined by the red dashed box magnified at low power (middle, scale bar 200μm) and a second field at high power (right, scale bar 50μm). Numerous reactive AT2 cells (red arrowheads) exhibiting nucleomegaly and abundant cytoplasm can be seen demonstrating strong ACE2 staining.

C) Quantitative IHC for ACE2 was carried out on samples from ventilated patients (n = 12 samples from 11 patients). Total ACE2 expression from 5 low power fields is plotted relative to the patient’s age at the time of specimen collection. A linear fit to the data is indicated by the dashed line with the 95% confidence interval highlighted in grey. D) The same specimens quantitated in (C) were normalized by cellularity and the average ACE2 expression per cell is plotted along with a linear fit to the data and its 95% confidence interval. The red arrow in (C) and (D) indicates a patient providing 1 sample from the left lung and 1 sample from the right lung during the same procedure, utilized as a control for intra-individual reproducibility. The green and blue circle in (C) and (D) indicate the staining intensity of the samples depicted in Fig 5A and 5B, respectively. Sections were stained for ACE2 using DAB and counterstained with hematoxylin.

https://doi.org/10.1371/journal.pone.0247060.g003
cellularity (Fig 3D) which revealed a significant increase with age (p = 0.004 and p = 0.003, respectively, linear regression). As a control for precision, 1 of the 11 patients had a double lung explant with 2 samples collected contemporaneously (1 from the left lung and 1 from the right lung). In this 67 year-old-man, the pathological findings were the same for each sample (S2 Table in S1 File). Importantly, both specimens yielded similar results when quantified for ACE2, indicating that our procedure measured its expression with good intra-individual reproducibility (Fig 3C and 3D). Excluding either of these samples did not change the effect of age on ACE2 expression (p = 0.009 by area and p = 0.003 by cellularity excluding the right lung; p = 0.008 by area and p = 0.006 by cellularity excluding the left lung, linear regression).

Alveolar macrophages comprised a minor fraction of total cells in samples from ventilated patients (median 3.4%, range 1.7% - 10.9%) and by visual inspection did not show the prominent age-related change in ACE2 expression seen in AT2 cells. To determine whether the abundance of alveolar macrophages contributes strongly to the effect of age on ACE2 expression, we quantified the number of alveolar macrophages in each sample. When normalized to either tissue area (S6A Fig in S1 File) or cellularity (S6B Fig in S1 File), the number of alveolar macrophages did not change with age (p = 0.768 and p = 0.427, respectively, linear regression).

We considered that factors other than age might be determining the intensity of ACE2 staining in lung samples from ventilated patients. Therefore, we studied a number of features including the length of time the sample was archived, the ventilation parameters used proximal to sample collection (namely FiO2 and PEEP), the severity of DAD, the presence or absence of ILD, history of smoking, and patient sex. None of these features correlated significantly with ACE2 expression when normalized to either tissue area or cellularity (Table 1 and S7A–S7D Fig in S1 File).

To compare our results in ventilated patients to samples collected from spontaneously breathing individuals, we collected an additional set of 20 lung samples from patients who underwent lung excision/biopsy for either pneumothorax repair or metastatic non-pulmonary neoplasms (S2 Table in S1 File). In all cases, care was taken to select portions of adjacent uninvolved lung parenchyma to analyze for ACE2 expression by IHC. Similar to our control sections, ACE2 staining was largely found within AT2 cells and alveolar macrophages (Fig 4A and 4B). When compared across ages, there was no significant difference either upon visual

Table 1. Comparison of lung ACE2 expression with control features.

| Continuous Variables | ACE2 Per Area (ACE2 Integrated Density / 5 Fields of View) | ACE2 Per Cell (ACE2 Integrated Density / Cell) |
|----------------------|--------------------------------------------------------|-----------------------------------------------|
| Feature              | Coefficient    | p value | Coefficient    | p value |
| Year Collected (per year) | 36842745 | 0.323 | 7544.049 | 0.408 |
| FiO2 (per percent)   | -1417439  | 0.812 | -120.313 | 0.934 |
| PEEP (per cm H2O)    | 24662684  | 0.408 | 8111.722 | 0.255 |
| DAD Score (per scale unit [0–24]) | 37546086 | 0.443 | 10003.1 | 0.399 |
| Categorical Variables | p value | p value | p value | p value |
| ILD                  | 0.933      |       | 0.933      |       |
| History of Smoking   | 1          | 0.53   | 0.282      |       |
| Sex                  | 0.482      | 0.282  |           |       |

ACE2 staining intensity was compared to various features derived from chart review of patients contributing samples to the ventilated cohort (n = 12 samples from 11 patients). For continuous variables a linear model was fit and the resulting β coefficient for that feature and its significance is indicated. For categorical variables the significance of a Wilcoxon rank-sum test is indicated.

https://doi.org/10.1371/journal.pone.0247060.t001
Fig 4. ACE2 protein expression does not change with age in non-ventilated patients. A) Representative images of lung stained for ACE2 from a 26-year-old female who underwent blebectomy for a spontaneous pneumothorax are shown using a 1x objective (left, scale bar 3mm) with the region outlined by the red dashed box magnified at low power (middle, scale bar 200μm) and a second field at high power (right, scale bar 50μm). The normal alveolated lung parenchyma reveals AT2 cells which are positive for ACE2 (red arrowheads) scattered among largely ACE2 low type I pneumocytes. B) Representative images of lung stained for ACE2 from a 77-year-old man undergoing wedge resection for suspected metastatic angiosarcoma are shown using a 1x objective (left, scale bar 3mm) with the region outlined by the red dashed box magnified at low power (middle, scale bar 200μm) and a second field at high power (right, scale bar 50μm). Histologic findings in the normal alveolated parenchyma adjacent to the lesion were similar to those found in (A) with strong ACE2 staining in scattered AT2 cells (red arrowheads) and occasional alveolar macrophages. C) Quantitative IHC for ACE2 was carried out on samples from non-ventilated patients (n = 20 patients). Total ACE2 expression from 5 low power fields is plotted relative to the patient's age at the time of specimen collection. A linear fit to the data is indicated by the dashed line with the 95% confidence interval highlighted in grey. D) The same specimens quantitated in (C) were normalized by cellularity and the average ACE2 expression per cell is plotted along with a linear fit to the data and its 95% confidence interval. Sections were stained for ACE2 using DAB and counterstained with hematoxylin.

https://doi.org/10.1371/journal.pone.0247060.g004
inspection or when quantified normalizing to tissue area (p = 0.231, linear regression) (**Fig 4C** or cellularity (p = 0.349, linear regression) (**Fig 4D**).

During our image acquisition, we noticed 2 cases exhibiting prominent ACE2 expression within the lung vascular endothelium (**Fig 5A and 5B**). This feature was not observed in any of the other 29 cases we examined. Upon chart review, we discovered that the first case was from a 53-year-old man who was actively receiving inpatient lisinopril at the time of lung explant (**Fig 5A**). The second case was from an 83-year-old man receiving valsartan during his immediately preceding admission at an outside institution, and at the time of transfer to our hospital, where his surgical resection occurred on post transfer day 4 (**Fig 5B**). Both patients were on supportive mechanical ventilation for AHRF prior to lung sample collection. The prominent age-related changes in AT2 cell ACE2 expression were again evident, but in addition, there was strong staining within the endothelium, indicating increased ACE2 expression within the vasculature. None of the other 29 cases in our dataset were from patients on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) (**S2 Table in S1 File**).

**Discussion**

After the recognition that SARS-CoV-2 depends on ACE2 for host infection [23], a number of key studies have linked the expression of this viral receptor to tissue susceptibility. Within the

![Fig 5. Two patients on ACEI/ARB therapy exhibit intense endothelial ACE2 expression. A) Representative images of lung stained for ACE2 from a 53-year-old man with organizing diffuse alveolar damage superimposed on fibrosing interstitial lung disease are shown using a 1x objective (left, scale bar 3mm) with the region outlined by the red dashed box magnified at low power (middle, scale bar 200μm) and second field at high power (right, scale bar 50μm). AT2 cell hyperplasia can be seen with lower level ACE2 expression present along the alveolar septum (green arrowheads). Strongly stained endothelial cells (red arrowheads) can be seen throughout the entire specimen from this patient who was on daily lisinopril at the time of specimen collection. B) Representative images of lung stained for ACE2 from an 83-year-old man in the organizing phase of diffuse alveolar damage are shown using a 1x objective (left, scale bar 3mm) with the region outlined by the red dashed box magnified at low power (middle, scale bar 200μm) and second field at high power (right, scale bar 50μm). In addition to high ACE2 expression in reactive AT2 cells (green arrowheads), strong staining can be seen in numerous vascular endothelial cells (red arrowheads) throughout the thickened septal area in this patient on valsartan 4 days prior to specimen collection. Sections were stained for ACE2 using DAB and counterstained with hematoxylin.](https://doi.org/10.1371/journal.pone.0247060.g005)
mammalian body, expression of ACE2, along with transmembrane serineprotease 2 (TMPRSS2)—the human protease responsible for activating the SARS-CoV-2 spike protein—coincides with cell types involved by Covid-19 [40]. ACE2 protein is highly expressed in differentiated gut enterocytes, leading to productive infection with SARS-CoV-2 [41]. Interestingly, ACE2 expression is upregulated in the airway and lungs of smokers [29], a potential risk factor for severe disease [42]. Additionally, children have lower ACE2 RNA expression in their nasal epithelium compared with adults [43]. A growing body of evidence suggests that ACE2 is highly associated with cellular susceptibility and disease severity [23, 44]. Given that the mechanism of death in Covid-19 typically involves severe lower respiratory tract infection, a disease feature strongly correlated with age, previous studies have sought to connect lung ACE2 expression with aging [28, 29]. Although we analyzed a subset of the same publicly available data, we highlight the critical impact of mechanical ventilation on ACE2 expression, an important physiologic change for the lung. By incorporating this feature into our model, we find that ACE2 expression indeed increases in older individuals through what is likely a combination of advanced age, and either the need for or consequence of mechanical ventilation.

Reactive AT2 hyperplasia has long been recognized as a common finding after alveolar epithelial damage [45–48]. Patients in our ventilator supported cohort uniformly exhibited DAD with abundant hypertrophic AT2 cells. Our IHC analyses reveal that AT2 cells, as well as alveolar macrophages, are the primary cell types expressing ACE2 in the alveolus. Although we cannot rule out a subtle shift, changes in ACE2 expression among alveolar macrophages was minor when compared visually to AT2 cells and the former’s abundance showed no relationship with age in ventilated patients. Rather, the age-related increase in ACE2 expression we observed appears to be primarily mediated by the level of this protein’s expression in individual AT2 cells, with a potential lower contribution from other cells types. This trend was not seen in spontaneously breathing patients suggesting that the response of AT2 cells to alveolar injury drives this change.

Previous experiments have revealed that ACE2 expression has a special relationship with the cell cycle in AT2 cells responding to injury [49, 50]. For example, lung ACE2 mRNA, protein, and enzymatic activity are dramatically reduced in patients with idiopathic pulmonary fibrosis (IPF), a type of chronic lung injury [49]. The same work revealed that these changes are produced in both rats and mice in response to experimental lung injury induced by bleomycin. A follow-up experiment revealed the underlying cellular mechanism for this response [50]. Similar to our results, a lung biopsy from a normal control lung revealed strong ACE2 expression in AT2 cells, which was lost in a patient with IPF coincident with the expression of PCNA in proliferating lung epithelial cells. Furthermore, A549 cells, a malignant human cell line of AT2 origin, express high levels of ACE2 when quiescent in culture, but rapidly reduce this expression upon cell cycle entry [50]. In the lungs of healthy control mice, stimulation of AT2 cell proliferation by keratinocyte growth factor was followed by the loss of ACE2 expression, which was restored 2 weeks later upon re-entry into quiescence [50]. Taken together these data reveal that ACE2 expression is ordinarily high in resting AT2 cells but can be lost upon mitotic entry driven by either injury or growth factor stimulation, contributing significantly to total lung ACE2 levels. This phenomenon could explain reduced expression in patients with DAD, but how might increased expression be seen in older patients who also exhibit AT2 hyperplasia in response to injury? A recent study has revealed that ACE2 expression is upregulated in human respiratory cells in response to inflammatory signals including IFNα2 and IFNγ [40]. Immune changes associated with aging include the chronic, low-grade endogenous production of inflammatory cytokines, frequently referred to as “inflammaging”, which is caused by a number of processes [51–54]. One potential model for the age-related differences we observe would be that in response to alveolar damage, AT2 cells enter the cell...
cycle and ordinarily downregulate ACE2 expression. However, in older individuals, the increase in circulating inflammatory cytokines prevents this downregulation or even leads to ACE2 upregulation alongside AT2 cell proliferation. Alternatively, age associated epigenetic dysregulation may preclude the proper downregulation of ACE2 in proliferating AT2 cells [22]. Evidence for this second model derives from specific methylic patterns, which shift during aging, leading to the proposal that these changes underlie an attenuated response to environmental cues in older organisms [55]. Indeed, in human airway epithelial cells, DNA methylation of the ACE2 promoter is decreased with age, predicting increased expression [56].

The above models imply that the relationship of aging to ACE2 expression is associated with the need for mechanical ventilation (i.e., the alveolar damage itself) instead of being caused by it. However, the reverse scenario also merits consideration. Positive pressure ventilation is associated with lung injury (ventilator-associated lung injury or VALI) and is sometimes the underlying cause of such injury (ventilator-induced lung injury or VILI) [57]. The pathological features of VILI are indistinguishable from other causes of ARDS and are induced by volume and pressure stress within the alveolus [58]. Ventilation strategies that result in VILI provoke higher levels of inflammatory cytokine release [59, 60]. In animal models, advanced age is associated with an increased likelihood of VILI [61] and exacerbated cytokine release in response to ventilation [62]. If lung ACE2 expression is triggered by mechanical ventilation itself via inflammatory cytokine production, then these factors may predispose older individuals to severe SARS-CoV-2 infection. The relative contributions of these and other potential mechanisms remain to be explored, however therapeutic strategies aimed at the underlying pathways could be envisioned. For example, reducing age associated inflammation may lower ACE2 expression in proliferating AT2 cells and limit infection of damaged alveolar epithelium. Indeed, the RECOVERY trial has revealed that dexamethasone reduces mortality in Covid-19 patients, with the greatest benefits achieved by those receiving mechanical ventilation [63]. The Janus kinase (JAK) pathway is downstream of many inflammatory cytokines associated with aging [64]. Results reported from a recent double-blind randomized control trial have shown that the JAK1/2 inhibitor, baricitinib, reduces time to recovery and improves outcomes in Covid-19 patients [65, 66]. Whether these therapeutics confer benefit, at least in part, by modulating ACE2 expression could be a point of future investigation.

Even though ACE2 expression correlates with cellular vulnerability to SARS-CoV-2 infection [23], decreased tissue levels are associated with physiologic worsening of acute lung injury (ALI) [67]. In mouse models of ALI, induced by either acid aspiration or sepsis, Ace2 knockout results in more severe damage which can be rescued by intraperitoneal injection of recombinant ACE2 [68]. This effect appears to owe to increased levels of angiotensin II within the lung, as the severity of symptoms can be reversed by genetic disruption of Ace along with Ace2, and pharmacologic or genetic inhibition of angiotensin II signaling ameliorates lung injury. Interestingly, reduced ACE2 abundance in the lung can be triggered by SARS-CoV infection or intraperitoneal injection SARS-CoV spike protein alone [69]. Binding of SARS-CoV spike protein to ACE2 triggers its proteolytic cleavage by TNF-α-converting enzyme (TACE), providing a mechanism for this decrease [70]. The observed reduction in ACE2 levels leads to exacerbation of lung injury in mouse models. Thus ACE2 expression appears to confer susceptibility to viral infection at the cellular level yet protection from lung injury at the tissue level, how these opposing forces contribute to overall severity in the setting of SARS-CoV-2 infection requires additional study.

ACE2 expression alone likely cannot explain the cellular targets of SARS-CoV-2. Indeed, its spike protein diverges from SARS-CoV and the closely related bat coronavirus RaTG13 by the acquisition of the amino acids PRRA, conferring a furin cleavage site between the S1 and S2
subunits [71]. Cleavage at this site facilitates the adoption of an open conformation, exposing
the receptor-binding domain of SARS-CoV-2 spike, and is provided by the ubiquitously
expressed convertase furin [72]. The secondary cleavage of SARS-CoV-2 spike occurs at the
S2’ site which exposes the fusion peptide and leads to viral envelope merger with host cell
membrane [73]. This proteolytic step is mediated primarily by TMPRSS2, although some
priming may occur via cathepsin B and L [23]. The cellular distribution of TMPRSS2 is more
restricted than furin, however TMPRSS2 is highly expressed by AT2 cells [40]. Thus if produc-
tive infection requires all 3 proteins, the level of ACE2 expression may confer the crucial ele-
ment limiting viral propagation in severe disease.

Although our study was originally designed to characterize the effects of age and ventilation
on ACE2 expression, during data acquisition, the presence of strong vascular ACE2 staining in
2 cases was striking. This prompted us to investigate the underlying cause. Chart review
uncovered that 1 patient was receiving an ACEI at the time of sample collection and the second
was receiving an ARB just prior to collection. The remaining 29 cases were taken from patients
not receiving either class of medication. ACE2 has been shown previously to be upregulated by
ACEI/ARB therapy in the rodent heart [74] and human intestine [75], raising the concern that
these therapeutics may predispose to SARS-CoV-2 infection [76]. Observational studies have
indicated that the use of ACEI/ARBs does not increase the chances of testing positive for
SARS-CoV-2 [77] and reduces the chances of Covid-19 mortality [78]. Randomized trials to
assess the impact of ACEI/ARB discontinuation in Covid-19 are currently planned and ongo-
ing [79, 80]. Although we identified elevated pulmonary endothelial ACE2 expression in the
only 2 patients on ACEI/ARBs in our cohort, this finding is preliminary and requires replica-
tion. A recent study has demonstrated pulmonary vascular endothelialitis associated with
SARS-CoV-2 infection of these cells [9]. Whether increased endothelial ACE2 expression
modulates this disease feature or Covid-19 pathogenesis in general is currently unknown.

Limitations
In this small series of cases, we identified increased ACE2 RNA and ACE2 protein expression
within the human lung associated with age, when controlling for ventilator status. Although
our RNAseq analyses drew on the sample rich resource of the GTEx dataset, including 578
unique donor lung samples, our quantitative IHC results derived from limited archival sam-
ple samples (12 samples from 11 patients). However, the concordance between our findings at the
RNA and protein level revealing an interaction of mechanical ventilation and age in both
cases, strengthens our conclusions.

Supporting information
S1 File.
(DOCX)

Acknowledgments
We would like to thank the staff of the Stanford Medicine Department of Pathology for excel-
ence in patient care throughout the current pandemic and selfless diligence in cataloguing,
processing, and reporting the original case material contributing to this study. We also extend
our sincere appreciation to Norman Cyr for assistance with image acquisition and processing
and Erna Forgo for help with image acquisition and initial interpretation. This manuscript has
been released as a pre-print at medRxiv, medRxiv 2020.07.05.20140467 [81].
Author Contributions

Conceptualization: Steven Andrew Baker, Gerald J. Berry, Thomas J. Montine.

Formal analysis: Steven Andrew Baker.

Funding acquisition: Gerald J. Berry, Thomas J. Montine.

Investigation: Steven Andrew Baker, Shirley Kwok, Gerald J. Berry, Thomas J. Montine.

Methodology: Steven Andrew Baker, Gerald J. Berry, Thomas J. Montine.

Resources: Gerald J. Berry, Thomas J. Montine.

Supervision: Gerald J. Berry, Thomas J. Montine.

Validation: Steven Andrew Baker.

Writing – original draft: Steven Andrew Baker.

Writing – review & editing: Steven Andrew Baker, Gerald J. Berry, Thomas J. Montine.

References

1. Dhama K, Patel SK, Pathak M, Yatoo MI, Tiwari R, MalikYS, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Medicine and Infectious Disease. 2020; 101755. https://doi.org/10.1016/j.tmaid.2020.101755 PMID: 32479816

2. Majdjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronavirus on the Cardiovascular System: A Review. JAMA Cardiology. 2020 [cited 7 Jun 2020]. https://doi.org/10.1001/jamacardio.2020.1286 PMID: 32219363

3. Hao S-R, Zhang S-Y, Lian J-S, Jin X, Ye C-Y, Cai H, et al. Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. American Journal of Gastroenterology. 9000; Publish Ahead of Print. Available: https://journals.lww.com/ajg/Fulltext/9000/Liver_Enzyme_Elevation_in_Coronavirus_Disease.99268.aspx https://doi.org/10.14309/ajg.0000000000000717 PMID: 32618658

4. Niazzkar HR, Zibae B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurological Sciences. 2020. https://doi.org/10.1007/s10072-020-04486-3 PMID: 32483687

5. Zhou Y, Duan C, Zeng Y, Tong Y, Nie Y, Yang Y, et al. Ocular Findings and Proportion with Conjunctival SARS-COV-2 in COVID-19 Patients. Ophthalmology. 2020; S0161-6420(20)30405-X. https://doi.org/10.1016/j.opth.2020.04.028 PMID: 32359840

6. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis. 2020.n/a. https://doi.org/10.1111/jth.14854 PMID: 32302448

7. Selby NM, Forini LG, Laing CM, Horne KL, Evans RD, Lucas BJ, et al. Covid-19 and acute kidney injury in hospital: summary of NICE guidelines. BMJ. 2020; 369: m1963. https://doi.org/10.1136/bmj.m1963 PMID: 32457068

8. Sultan S, Altayar O, Siddiqe SM, Davltnov P, Feuerstein JD, Lim JK, et al. AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. 2020; S0016-5085(20)30593-X. https://doi.org/10.1053/j.gastro.2020.05.001 PMID: 32407808

9. Ackermann M, Verleden SE, Kuehnelt M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 [cited 6 Jun 2020]. https://doi.org/10.1056/NEJMoas2015432 PMID: 32437596

10. Schaller T, Hirschbühl K, Burkhardt K, Braun G, Trepel M, Märkl B, et al. Postmortem Examination of Patients With COVID-19. JAMA. 2020 [cited 7 Jun 2020]. https://doi.org/10.1001/jama.2020.8907 PMID: 32437497

11. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020.n/a. https://doi.org/10.1111/his.14134 PMID: 32364264

12. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in...
the New York City Area. JAMA. 2020; 323: 2052–2059. https://doi.org/10.1001/jama.2020.6775 PMID: 32320003

13. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020; 108: 154262–154262. https://doi.org/10.1016/metabol.2020.154262 PMID: 32422233

14. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; S0140-6736(20)31187-9. https://doi.org/10.1016/S0140-6736(20)31187-9 PMID: 32473681

15. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55; 2000547. https://doi.org/10.1183/13993003.00547-2020 PMID: 32217650

16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020; 395: 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076

17. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020; 8: 475–481. https://doi.org/10.1016/S2213-2600(20)30152-1 PMID: 32224304

18. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. N Enng J Med. 2020; 382; 2012–2022. https://doi.org/10.1056/NEJDmou2004500 PMID: 32277758

19. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 [cited 25 Apr 2020]. https://doi.org/10.1001/jama.2020.5394 PMID: 32250385

20. Sinha IP, Harwood R, Semple MG, Hawcutt DB, Thursfield R, Narayan O, et al. COVID-19 infection in children. The Lancet Respiratory Medicine. 2020; 8: 446–447. https://doi.org/10.1016/S2213-2600(20)30152-1 PMID: 32244034

21. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality Associated with Influenza and Respiratory Syncytial Virus in the United States. JAMA. 2003; 289: 179–186. https://doi.org/10.1001/jama.289.2.179 PMID: 12517228

22. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020; 12: 9959–9961. https://doi.org/10.18632/aging.103344 PMID: 32470948

23. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181: 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651

24. Touyz Rhian M., Montezano Augusto C. Angiotensin (1–7) and Vascular Function. Hypertension. 2018; 71: 68–69. https://doi.org/10.1161/HYPERTENSIONAHA.117.10406 PMID: 29203630

25. Gambard F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss H-P, et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides. 2005/02/16 ed. 2006; 27: 1270–1277. https://doi.org/10.1016/j.peptides.2005.01.009 PMID: 15949646

26. Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2005/11/21 ed. 2006; 78: 2166–2171. https://doi.org/10.1016/j.lfs.2005.09.038 PMID: 16303146

27. AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. JAMA Cardiology. 2020 [cited 7 Jun 2020]. https://doi.org/10.1001/jamacardio.2020.1329 PMID: 32242886

28. Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious Diseases of Poverty. 2020; 9: 45. https://doi.org/10.1186/s40249-020-00662-x PMID: 32345362

29. Smith JC, Sausville EL, Girish V, Yuan ML, Vasudevan A, John KM, et al. Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract. Developmental Cell. 2020. https://doi.org/10.1016/devcell.2020.05.012 PMID: 32425701

30. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. Nature Genetics. 2013; 45: 580–585. https://doi.org/10.1038/ng.2653 PMID: 23715323

31. Gry M, Rimini R, Strömberg S, Asplund A, Pontén F, Uhlén M, et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics. 2009; 10: 365. https://doi.org/10.1186/1471-2164-10-365 PMID: 19660143
32. Edfors F, Danielsson F, Hallström BM, Käll L, Lundberg E, Pontén F, et al. Gene-specific correlation of RNA and protein levels in human cells and tissues. Mol Syst Biol. 2016; 12: 883–883. https://doi.org/10.1525/msb.20167144 PMID: 27951527

33. GTEx Consortium. GTEx Portal. [cited 22 Apr 2020]. Available: https://www.gtexportal.org/home/

34. Schaur M, Karkanas J, Neff NF, May AP, Quake SR, Wyss-Coray T, et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature. 2018; 562: 367–372. https://doi.org/10.1038/s41586-018-0590-4 PMID: 30283141

35. Tabula Muris. Tabula Muris Portal. [cited 5 Jun 2020]. Available: https://tabula-muris.ds.czbiohub.org/

36. Spieth PM, Kneis L, Kasper M, Domingues Quehlas A, Wiedemann B, Lupp A, et al. Effects of vaporized perfluorohexane and partial liquid ventilation on regional distribution of alveolar damage in experimental lung injury. Intensive Care Medicine. 2007; 33: 308–314. https://doi.org/10.1007/s00134-006-0428-7 PMID: 17091244

37. GTEx Consortium. Hardy scale description. [cited 5 Jun 2020]. Available: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/variable.cgi?study_id=phs000424.v4.p1&phv=169092#;--:text=Death%20classification%20based%20on%20the,phase%20estimated%20at%20%.3C%2010%20min.

38. Ferreira PG, Muñoz-Aguirre M, Reverter F, Sá Godinho CP, Sousa A, Amadoz A, et al. The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nature Communications. 2018; 9: 490. https://doi.org/10.1038/s41467-017-02772-x PMID: 29440659

39. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology. 2004; 203: 631–637. https://doi.org/10.1002/path.1570 PMID: 15141377

40. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020; 181: 1016–1035.e19. https://doi.org/10.1016/j.cell.2020.04.035 PMID: 32413319

41. Lamers MM, Beumer J, van der Vaart J, Knoop K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productionally infects human gut enterocytes. Science. 2020; eabc1669. https://doi.org/10.1126/science.abc1669 PMID: 32358202

42. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. Journal of Medical Virology. 2020;n/a. https://doi.org/10.1002/jmv.25889 PMID: 32293753

43. Miller BE, Hook GE. Hypertrophy and hyperplasia of alveolar type II cells in response to silica and other pulmonary toxicants. Environmental Health Perspectives. 1990; 85: 15–23. https://doi.org/10.1289/ehp.85-156821 PMID: 2166657

44. Pinto BGG, Oliveira AER, Singh Y, Jimenez L, Gonçalves ANA, Ogava RLT, et al. ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. The Journal of Infectious Diseases. 2020; 222: 556–563. https://doi.org/10.1093/infdis/jja332 PMID: 32526012

45. Miller BE, Hook GE. Hypertrophy and hyperplasia of alveolar type II cells in response to silica and other pulmonary toxicants. Environmental Health Perspectives. 1990; 85: 15–23. https://doi.org/10.1289/ehp.85-156821 PMID: 2166657

46. Evans MJ, Dekker NP, Cabral-Andersen LJ, Freeman G. Quantitation of Damage to the Alveolar Epithelium by Means of Type 2 Cell Proliferation. Am Rev Respir Dis. 1978; 118: 787–790. https://doi.org/10.1164/arrd.1978.118.4.787 PMID: 707897

47. Stanley MW, Henry-Stanley MJ, Gajj-Peczalska KJ, Bitterman PB. Hyperplasia of Type II Pneumocytes in Acute Lung Injury: Cytologic Findings of Sequential Bronchoalveolar Lavage. American Journal of Clinical Pathology. 1992; 97: 669–677. https://doi.org/10.1093/ajcp/97.5.669 PMID: 1575213

48. Takemura T. Histopathological Study of the Adverse Effects of Prolonged Respiratory Therapy on the Neonate Lung. Pathology International. 1981; 31: 199–210. https://doi.org/10.1111/j.1440-1614.1981.tb01365.x PMID: 7257763

49. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2008; 295: L178–L185. https://doi.org/10.1152/ajplung.00009.2008 PMID: 18441099

50. Uhal BD, Dang M, Dang V, Llutos R, Cano E, Abdul-Hafez A, et al. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. Eur Respir J. 2013; 42: 198. https://doi.org/10.1183/09031936.0015612 PMID: 23100504

51. Kang C, Xu Q, Martin TD, Li MZ, Demaria M, Aron L, et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science. 2015; 349: aaa5612. https://doi.org/10.1126/science.aaa5612 PMID: 26404840
52. De Cecco M, Ito T, Petrasen AP, Elias AE, Skvir, Criscione SW, et al. Lung ACE2 expression increases with age in the setting of mechanical ventilation. Nature. 2019; 566: 73–78. https://doi.org/10.1038/s41586-018-0784-9 PMID: 30728521
53. Mahmoudi S, Mancini E, Xu L, Moore A, Jahanbani F, Hebestreit K, et al. Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing. Nature. 2019; 574: 553–558. https://doi.org/10.1038/s41586-019-1658-5 PMID: 31645721
54. Franceschi C, Campisi J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. The Journals of Gerontology; Series A. 2014; 69: S4–S9. https://doi.org/10.1093/gerona/glu057 PMID: 24833586
55. Li Y, Tollefsbol TO. Age-related epigenetic drift and phenotypic plasticity loss: implications in prevention of age-related human diseases. Epigenomics. 2016/11/24 ed. 2016; 8: 1637–1651. https://doi.org/10.2217/epi.16-0078 PMID: 27882781
56. Corley M, Ndhlovu L. DNA Methylation Analysis of the COVID-19 Host Cell Receptor, Angiotensin I Converting Enzyme 2 Gene (ACE2) in the Respiratory System Reveal Age and Gender Differences. Preprints. 2020;2020030295. https://doi.org/10.20944/preprints202003.0295.v1
57. Slutsky AS, Ranieri VM. Ventilator-Induced Lung Injury. N Engl J Med. 2013; 369: 2126–2136. https://doi.org/10.1056/NEJMra1208707 PMID: 24283226
58. Madahar P, Beitler JR. Emerging concepts in ventilation-induced lung injury. F1000Res. 2020; 9: https://doi.org/10.12688/f1000research.20576.1 PMID: 32269759
59. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, et al. Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With Acute Respiratory Distress SyndromeA Randomized Controlled Trial. JAMA. 1999; 282: 524–531. https://doi.org/10.1001/jama.282.1.52 PMID: 10404912
60. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Critical Care Medicine. 2005;33.
61. Nin N, Lorente JA, De Paula M, Fernández-Segoviano P, Peñuelas O, Sánchez-Ferrer A, et al. Aging increases the susceptibility to injurious mechanical ventilation. Intensive Care Medicine. 2008; 34: 923–931. https://doi.org/10.1007/s00134-007-0960-0 PMID: 18180905
62. Andrade PV, dos Santos JM, Silva HCA, Wilbert DD, Cavassani SS, Oliveira-Júnior IS. Influence of Hyperoxia and Mechanical Ventilation in Lung Inflammation and Diaphragm Function in Aged Versus Adult Rats. Inflammation. 2014; 37: 486–494. https://doi.org/10.1007/s10753-013-9762-4 PMID: 24158570
63. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mathem M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. N Engl J Med. 2020; NEJMoa2021436. https://doi.org/10.1056/NEJMoa2021436 PMID: 32678530
64. Aaronson DS, Horvath CM. A Road Map for Those Who Don’t Know JAK-STAT. Science. 2002; 296: 1653. https://doi.org/10.1126/science.1071545 PMID: 12040185
65. Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Drugs. 2020; 80: 1929–1946. https://doi.org/10.1007/s40265-020-01421-w PMID: 33068263
66. Lilly Eli. Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial. 2020 Sep. Available: https://investor.lilly.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery
67. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine. 2020; 46: 586–590. https://doi.org/10.1007/s00134-020-05985-9 PMID: 32125455
68. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436: 112–116. https://doi.org/10.1038/nature03712 PMID: 16001071
69. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Medicine. 2005; 11: 875–879. https://doi.org/10.1038/nm1267 PMID: 16007097
70. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, et al. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci USA. 2008; 105: 7809. https://doi.org/10.1073/pnas.0711241105 PMID: 18490652
71. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nature
72. Braun E, Sauter D. Furin-mediated protein processing in infectious diseases and cancer. Clin Transl Immunology. 2019; 8: e1073–e1073. https://doi.org/10.1002/cti2.1073 PMID: 31406574

73. Bestle D, Heindl MR, Limburg H, Van Lam van T, Pilgram O, Moulton H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020; 3: e202000786. https://doi.org/10.26508/lsa.202000786 PMID: 32703818

74. Ferrario Carlos M., Jessup Jewell, Chappell Mark C., Averill David B., Brosnihan K, Bridget, Tallant E., Ann, et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation. 2005; 111: 2605–2610. https://doi.org/10.1161/CIRCULATIONAHA.104.510461 PMID: 15897343

75. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015; 47: 693–705. https://doi.org/10.1007/s00726-014-1889-6 PMID: 25534429

76. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine. 2020; 8: e21. https://doi.org/10.1016/S2213-2600(20)30116-8 PMID: 32171062

77. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020 [cited 8 Jun 2020]. https://doi.org/10.1001/jamacardio.2020.1855 PMID: 32936273

78. Peng Zhang, Lihua Zhu, Jingjing Cai, Fang Lei, Qin Juan-Juan, Xie Jing, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research. 2020; 126: 1671–1681. https://doi.org/10.1161/CIRCRESAHA.120.317134 PMID: 32302265

79. ClinicalTrials.gov. Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID). In: Identifier: NCT04338009 [Internet]. [cited 6 Jun 2020]. Available: https://clinicaltrials.gov/ct2/show/NCT04338009

80. Lopes RD, Macedo AVS, e Barros e Silva PGM, Moll-Bernardes RJ, Feldman A, D’Andrea Saba Arruda G, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—The BRACE CORONA Trial. American Heart Journal. 2020; 226: 49–59. https://doi.org/10.1016/j.ahj.2020.05.002 PMID: 32502982

81. Baker SA, Kwok S, Berry GJ, Montine TJ. Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation. medRxiv. 2020; 2020.07.05.20140467. https://doi.org/10.1101/2020.07.05.20140467